Lefokcin

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Lefokcin: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Application during pregnancy and lactation
10. Use in childhood
11. In case of impaired renal function
12. For violations of liver function
13. Use in the elderly
14. Drug interactions
15. Analogs
16. Terms and conditions of storage
17. Terms of dispensing from pharmacies
18. Reviews
19. Price in pharmacies

Latin name: Lefokcin

ATX code: J01MA12

Active ingredient: levofloxacin (levofloxacin)

Manufacturer: Shreya Life Science Pvt. Ltd. (Shreya Life Sciences, Pvt. Ltd.) (India)

Description and photo updated: 30.11.2018

Prices in pharmacies: from 208 rubles.

Buy

Lefokcin is an antimicrobial drug of the fluoroquinolone group.

Release form and composition

The drug is available in the form of film-coated tablets (caplets *): oblong, biconvex, with a dividing line on one side; at a dose of 250 mg - light beige, at a dose of 500 mg - beige (3, 5, 6, 7 or 10 pieces in blisters, in a cardboard box 1, 2, 3 or 4 blisters and instructions for use of Lefokcin) …

1 tablet contains:

active substance: levofloxacin (in the form of levofloxacin hemihydrate) - 250 mg or 500 mg;
auxiliary components: microcrystalline cellulose, colloidal silicon dioxide, starch, sodium carboxymethyl starch, povidone-K30, magnesium stearate, talc;
shell composition: propylene glycol, hypromellose 15,000, iron dye yellow oxide, iron dye red oxide, titanium dioxide, talc.

* tablet in the form of a capsule, facilitating swallowing whole.

Pharmacological properties

Pharmacodynamics

Lefokcin is a synthetic antibacterial drug with a broad spectrum of action of the fluoroquinolone group. Its active substance is levofloxacin (levorotatory isomer of ofloxacin), which is active in vitro and in vivo against most strains of pathogenic microorganisms. The mechanism of action of levofloxacin is due to such properties as the ability to block DNA gyrase and topoisomerase IV, disrupt supercoiling and stitching of deoxyribonucleic acid (DNA) breaks, inhibit the process of its synthesis, which leads to deep morphological changes in the cytoplasm, membranes and cell wall of microbes.

In vitro sensitivity [MIC (minimum inhibitory concentration) not more than 2 mg / ml; zone of inhibition not less than 17 mm] the following infections show to the drug:

aerobic gram-positive microorganisms: Corynebacterium jeikeium, Corynebacterium diphtheriae, Bacillus anthracis, Enterococcus speciales (spp.), Enterococcus faecalis, Staphylococcus spp. CNS (coagulase-negative strains), Staphylococcus coagulase-negative methi-S (I) (coagulase-negative methicillin-susceptible or methicillin-moderately susceptible strains), Staphylococcus epidermidis methi-Scus (methicillin-aurehyllicillin-susceptible strains), strains), Listeria monocytogenes, Viridans Streptococci peni-S / R (penicillin-sensitive and penicillin-resistant strains), Streptococcus groups C and G, Streptococcus pneumoniae peni-I / S / R (penicillin-moderately sensitive, penicillin-sensitive penicillin -resistant strains), Streptococcus agalactiae, Streptococcus pyogenes;
aerobic gram-negative microorganisms: Acinetobacter spp., Acinetobacter baumannii, Actinobacillus actinomycetemcomitans, Eikenella corrodens, Citrobacter freundii, Enterobacter aerogenes, Enterobacter spp., Enterobacter cloacae, Escherichia coli / ampillin-susceptible ampillin, Haemophilicillin-sensitive, Haemophilus parainfluenzae, Haemophilus ducreyi, Gardnerella vaginalis, Helicobacter pylori, Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella spp., Morganella morganii, Moraxella catarrhalis (non-lactating and lactamisating) methystamycinum and betworming bacteria Pasteurella canis, Pasteurella multocida, Pasteurella dagmatis, Pasteurella spp., Proteus vulgaris, Proteus mirabilis, Providencia stuartii, Providencia rettgeri,Providencia spp., Pseudomonas spp., Pseudomonas aeruginosa, Serratia spp., Serratia marcescens, Salmonella spp.;
anaerobic microorganisms: Bifidobacterium spp., Bacteroides fragilis, Veillonella spp., Peptostreptococcus, Clostridium perfringens, Propionibacterium spp., Fusobacterium spp.;
other microorganisms: Ureaplasma urealyticum, Bartonella spp., Rickettsia spp., Chlamydia pneumoniae, Legionella spp., Legionella pneumophila, Mycobacterium spp., Mycobacterium tuberculosis, Chlamydia trachomatis, Chlamydia lecoplasium hominis, Chlamydia psitta, Mycobacterium

When treating nosocomial infections with Pseudomonas aeruginosa, combination therapy may be required.

Moderate activity (MIC is 4 mg / l; zone of inhibition is 16 to 14 mm) Lefokcin exhibits against the following microorganisms:

aerobic gram-positive microorganisms: Staphylococcus haemolyticus methi-R (methicillin-resistant strains), Staphylococcus epidermidis methi-R (methicillin-resistant strains), Corynebacterium xerosis, Corynebacterium urealycus fauna, Enterococium;
aerobic gram-negative microorganisms: Campylobacter jejuni, Campylobacter coli;
anaerobic microorganisms: Porphyromonas spp., Prevotella spp.

Resistance (MIC not less than 8 mg / l; zone of inhibition not more than 13 mm) to levofloxacin is shown by the following microbes:

aerobic gram-positive microorganisms: Staphylococcus coagulase-negative methi-R (coagulase-negative methicillin-resistant), Staphylococcus aureus methi-R (methicillin-resistant);
aerobic gram-negative microorganisms: Alcaligenes xylosoxidans;
anaerobic and other microorganisms: Bacteroides thetaiotaomicron; Mycobacterium avium.

Levofloxacin resistance develops in the process of stepwise mutation of genes encoding DNA gyrase and topoisomerase IV. In addition, resistance mechanisms such as active elimination of the antimicrobial agent from the microbial cell (efflux) and the mechanism of influence on the penetration barriers of the microbial cell can affect the decrease in the sensitivity of microorganisms to levofloxacin.

With the simultaneous use of levofloxacin with other antimicrobial agents, cross-resistance does not occur.

As a result of clinical studies, the effectiveness of Lefokcin has been established in the treatment of infections caused by the following microorganisms:

aerobic gram-positive microorganisms: Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumoniae;
aerobic gram-negative microorganisms: Enterobacter cloacae, Citrobacter freundii, Haemophilus parainfluenzae, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Moraxella (Branhamella) catarrhalis, Proteus mirabilis, Serratia marcescens, Morganosa
others: Mycoplasma pneumoniae, Legionella pneumophila, Chlamydia pneumoniae.

Pharmacokinetics

After oral administration, levofloxacin is rapidly absorbed, its absolute bioavailability is 99-100%. The maximum concentration (C _max) in the blood plasma after a single dose of levofloxacin at a dose of 500 mg is achieved in 1-2 hours and can range from 0.004 to 0.0064 mg / ml. The equilibrium concentration in the blood plasma occurs after 48 hours while taking 500 mg 1-2 times a day. Levofloxacin is characterized by the preservation of linear pharmacokinetics in the dose range from 50 to 1000 mg. Simultaneous food intake has practically no effect on the absorption of Lefoktsin.

Serum protein binding - from 30 to 40%.

The volume of distribution is 100 liters.

Levofloxacin penetrates well into such organs and tissues of the human body as the bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, alveolar fluid, cortical and cancellous bone tissue, cerebrospinal fluid, prostate tissue.

8–12 hours after taking levofloxacin at a dose of 150 mg, its concentration in urine is 0.044 mg / ml, and at a dose of 300 mg - 0.091 mg / ml.

In the liver, up to 5% of the taken dose of levofloxacin is biotransformed by oxidation and / or deacetylation, resulting in the formation of two metabolites: demethyl levofloxacin, levofloxacin N-oxide. Being stereochemically stable, levofloxacin is not subject to chiral transformations.

The half-life (T _1/2) from blood plasma is 6-8 hours.

More than 85% of the active substance is excreted through the kidneys, including in the form of metabolites. After a single dose of 500 mg, the total clearance of levofloxacin ranges from 145.8 to 204.2 ml / min. The use of levofloxacin in the form of an intravenous solution or tablets is used interchangeably.

The patient's gender and age do not affect the pharmacokinetics of Lefoccin.

In renal failure, there is a change in such pharmacokinetic parameters of levofloxacin as a decrease in renal clearance and an increase in T _1/2. The dose of Lefoccin should be adjusted according to the degree of deterioration in renal function.

Indications for use

The use of Lefokcin is indicated for the treatment of the following diseases caused by bacterial infections susceptible to levofloxacin:

acute sinusitis;
community-acquired pneumonia;
exacerbation of chronic bronchitis;
uncomplicated and complicated urinary tract infections (including pyelonephritis);
infections of the skin and soft tissues;
chronic bacterial prostatitis;
drug-resistant forms of tuberculosis - as part of complex therapy;
anthrax of the airborne route of infection, including prevention.

Contraindications

Absolute:

an indication of a history of tendon lesions against the background of previous treatment with quinolones;
epilepsy;
pseudoparalytic myasthenia gravis;
period of pregnancy;
breast-feeding;
age under 18;
hypersensitivity to fluoroquinolones or drug components.

Caution should be exercised when prescribing Lefokcin to patients predisposed to the development of seizures (including cases of previous lesions of the central nervous system or concomitant therapy with fenbufen, theophylline and other drugs that reduce the seizure threshold of the brain), with latent or manifest deficiency of glucose-6-phosphate dehydrogenase, impairment renal function, diabetes mellitus, the presence of risk factors for prolongation of the QT interval (including female patients and the elderly; patients with hypokalemia, hypomagnesemia, congenital prolongation of the QT interval syndrome, heart failure, bradycardia, myocardial infarction; with the simultaneous use of class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics and other drugs,capable of lengthening the QT interval), mental illness (including history), the presence of cases of severe neurological reactions when taking other fluoroquinolones.

Lefokcin, instructions for use: method and dosage

Lefokcin tablets are taken orally, swallowing whole (the integrity of the film shell must not be violated) and drinking a sufficient amount of liquid (up to 200 ml) between meals or before meals.

When the patient is transferred to oral administration after preliminary treatment by intravenous infusion, the dose of levofloxacin is left unchanged.

The dose and treatment period are determined taking into account the clinical indications, the severity of the infection and the sensitivity of the pathogen to levofloxacin.

Recommended dosage:

acute sinusitis: 500 mg once a day, course duration 10-14 days;
community-acquired pneumonia: 500 mg 1-2 times a day, course duration 7-14 days;
exacerbation of chronic bronchitis: Lefokcin 500 mg once a day, course duration 7-10 days;
uncomplicated urinary tract infections: 250 mg 1 time per day, course duration 3 days;
complicated urinary tract infections (including pyelonephritis): 500 mg once a day; course duration 7-14 days, with pyelonephritis - 7-10 days;
infections of the skin and soft tissues: 500 mg 1-2 times a day, course duration 7-14 days;
chronic bacterial prostatitis: Lefokcin 500 mg once a day, course duration 28 days;
drug-resistant forms of tuberculosis: as part of complex therapy, 500 mg 1–2 times a day, course duration 90 days;
prevention and treatment of anthrax in case of infection by airborne droplets: 500 mg once a day, course duration 56 days.

If you accidentally miss taking the next dose of Lefoccin, it should be taken as soon as possible.

For the treatment of patients with impaired renal function with creatinine clearance (CC) of 50 ml / min and below, a decrease in the dose of the drug is required. Patients take the first dose of levofloxacin for all clinical indications in accordance with general recommendations. Further, the dosage regimen is adjusted taking into account the CC and the dose recommended for the treatment of a specific disease in patients with CC more than 50 ml / min.

The recommended dosage of Lefokcin in case of impaired renal function with CC 50–20 ml / min, depending on the indications:

250 mg once a day: the first dose is 250 mg, then 125 mg once a day;
500 mg once a day: the first dose is 500 mg, then 250 mg once a day;
500 mg 2 times a day: the first dose is 500 mg, then 250 mg 2 times a day.

The recommended dosage of Lefoccin in case of impaired renal function with CC 19-10 ml / min, depending on the indications:

250 mg once a day: the first dose is 250 mg, then 125 mg once every 2 days;
500 mg once a day: the first dose is 500 mg, then 125 mg once a day;
500 mg 2 times a day: the first dose is 500 mg, then 125 mg 2 times a day.

The recommended dosage of Lefokcin in case of impaired renal function with CC less than 10 ml / min (including patients on hemodialysis and continuous ambulatory peritoneal dialysis), depending on the indications:

250 mg once a day: the first dose is 250 mg, then 125 mg once every 2 days;
500 mg once a day: the first dose is 500 mg, then 125 mg once a day;
500 mg 2 times a day: the first dose is 500 mg, then 125 mg once a day.

After a hemodialysis session or continuous outpatient peritoneal dialysis, an additional dose of levofloxacin is not required.

Patients with impaired liver function do not need dose adjustment of Lefoktsin.

Changing the dosage regimen for elderly patients is required only if the patient's CC is 50 ml / min and below.

Taking Lefokcin tablets after normalization of body temperature or confirmed by the results of studies of the destruction of the pathogen is recommended to continue for at least 2-3 days.

Side effects

from the heart: rarely - palpitations, sinus tachycardia; frequency not established - prolongation of the QT interval, ventricular tachycardia, ventricular arrhythmias, ventricular tachycardia of the "pirouette" type (including cardiac arrest);
from the lymphatic system and blood: infrequently - leukopenia, eosinophilia; rarely - neutropenia, thrombocytopenia; frequency not established - pancytopenia, agranulocytosis, hemolytic anemia;
from the nervous system: often - headache, dizziness; infrequently - taste perversion, drowsiness, tremor; rarely - convulsions, paresthesia; frequency not established - extrapyramidal disorders, ageusia, parosmia (including loss of smell), peripheral sensory / sensory-motor neuropathy, dyskinesia, benign intracranial hypertension, syncope;
on the part of the organ of vision: very rarely - visual impairment (including blurring of the visible image); frequency not established - transient loss of vision;
from the organ of hearing and labyrinth disorders: infrequently - vertigo; rarely - ringing in the ears; frequency not established - hearing loss, hearing loss;
from the respiratory system, chest and mediastinal organs: infrequently - shortness of breath; frequency not established - allergic pneumonitis, bronchospasm;
from the gastrointestinal tract: often - nausea, vomiting, diarrhea; infrequently - dyspepsia, abdominal pain, flatulence, constipation; frequency not established - pancreatitis, hemorrhagic diarrhea, enterocolitis, pseudomembranous colitis;
from the urinary system: infrequently - increased serum creatinine levels; rarely - acute renal failure (including as a consequence of interstitial nephritis);
from the skin and its appendages: infrequently - itching, rash, urticaria, hyperhidrosis; frequency not established - stomatitis, photosensitization, leukocytoclastic vasculitis, exudative erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis;
from the musculoskeletal system and connective tissue: infrequently - myalgia, arthralgia; rarely - muscle weakness, tendon damage (including tendonitis); frequency not established - tendon rupture, rhabdomyolysis, ligament rupture, arthritis, muscle rupture;
from the side of metabolism and nutrition: infrequently - anorexia; rarely - hypoglycemia (more often in patients with diabetes mellitus); frequency not established - hypoglycemic coma, hyperglycemia;
infections and invasions: infrequently - development of resistance of pathogenic microorganisms, fungal infections;
from the side of the vessels: rarely - lowering blood pressure (BP);
from the immune system: rarely - angioedema; the frequency has not been established - anaphylactic shock and / or anaphylactoid shock (including while taking the first dose of Lefokcin);
from the hepatobiliary system: often - an increase in the activity of liver enzymes in the blood (including alanine aminotransferase, aspartate aminotransferase), an increase in the activity of gamma-glutamyl transferase, alkaline phosphatase; infrequently - an increase in the level of bilirubin in the blood; the frequency has not been established - severe liver failure, acute liver failure (including fatal outcome), jaundice, hepatitis;
mental disorders: often - insomnia; infrequently - anxiety, anxiety, confusion; rarely - agitation, sleep disturbances, nightmares, hallucinations, paranoia, depression; frequency not established - mental disorders (including behavioral disorders with self-harm, suicidal thoughts and / or attempts);
general disorders: infrequently - asthenia; rarely - an increase in body temperature; frequency not established - pain in the back, chest, extremities and other parts of the body.

In addition, in very rare cases, in patients with porphyria, against the background of the use of all fluoroquinolones, the development of attacks of porphyria is possible.

Overdose

Symptoms of a levofloxacin overdose: dizziness, confusion and / or impaired consciousness, seizures like epileptic seizures, nausea and other gastrointestinal disorders, erosive mucosal lesions, prolongation of the QT interval.

Treatment: there is no specific antidote, therefore, in case of an acute overdose of Lefoktsin, immediate gastric lavage, the introduction of antacids in order to protect the gastric mucosa are indicated. Symptomatic therapy. Monitoring of the patient's condition is required, including careful monitoring of the electrocardiogram.

Hemodialysis, peritoneal dialysis, or continuous peritoneal dialysis are not effective.

special instructions

For nosocomial infections caused by Pseudomonas aeruginosa, combination treatment may be required.

Due to the fact that the acquired resistance of plated strains of microorganisms can change in different geographic regions or over time, information is required on the prevalence of resistance to Lefoccin in a particular country.

In the absence of a therapeutic effect or treatment of severe infections, the diagnosis should be confirmed by the result of a microbiological study to determine the sensitivity to levofloxacin in the isolated pathogen.

The high probability of resistance of methicillin-resistant streptococcus aureus to levofloxacin should be taken into account. It is not recommended to prescribe Lefokcin if laboratory tests have not confirmed the sensitivity of the isolated microorganism to levofloxacin.

It is recommended to be especially careful when treating patients with a predisposition to seizures. These include patients with a history of stroke, severe traumatic brain injury, and other lesions of the central nervous system. In addition, the risk group includes patients who are on concomitant therapy with drugs that lower the seizure threshold of the brain (including non-steroidal anti-inflammatory drugs like fenbufen and drugs that lower the seizure threshold like theophylline).

During the period of treatment with Lefokcin, the existing risk of pseudomembranous colitis should be taken into account, including after the end of the drug. If a severe form of diarrhea (including blood) appears during therapy, the pill should be stopped immediately. During this period, the patients are contraindicated drugs that inhibit intestinal motility.

If symptoms of neuropathy develop, hypersensitivity reactions or adverse events from the skin and mucous membranes develop, Lefokcin should be stopped immediately and a doctor should be consulted.

Patients with renal insufficiency require a dosage adjustment and careful monitoring of renal function during the treatment period.

Quinolones may rarely rupture tendons, including the Achilles tendon. Tendon rupture, including bilateral tendon rupture, can occur during the first 48 hours of levofloxacin therapy. The risk of developing this undesirable effect of Lefokcin is increased in elderly patients and with concomitant glucocorticosteroid therapy. If tendonitis is suspected, treatment should be stopped immediately, the affected tendon is adequately immobilized, and appropriate treatment initiated.

During therapy and for 48 hours after its completion, patients should avoid exposure to direct sunlight or artificial ultraviolet radiation, including visiting a solarium.

Against the background of antibacterial therapy, especially long-term, it is possible to change the microflora, in which microorganisms insensitive to the antibiotic (bacteria and fungi) present in the human body begin to multiply intensively. In order to prevent the development of superinfection, during treatment, it is recommended to re-evaluate the patient's condition.

There are reports of cases of development of hepatic necrolysis, including fatal liver failure, while taking levofloxacin, mainly in severe underlying disease, such as sepsis. Patients should be informed about the need to immediately stop treatment and consult a doctor if symptoms of liver damage such as itching, abdominal pain, darkening of urine, anorexia, jaundice appear.

Patients with a history of psychosis or mental illness are at risk of developing psychotic reactions even after taking the first dose of Lefoccin. In very rare cases, their progression can cause the patient to develop suicidal thoughts or behavioral disorders with self-harm. If signs of psychotic reactions appear, treatment with this antibiotic should be discontinued and appropriate therapy initiated.

The use of Lefokcin may have a negative effect on the results of laboratory tests. False positive urinary opiates should be confirmed with more specific methods. Levofloxacin inhibition of the growth of Mycobacterium tuberculosis can lead to false positive results of the bacteriological diagnosis of tuberculosis.

Influence on the ability to drive vehicles and complex mechanisms

During the period of use of Lefokcin, it is possible to develop such undesirable effects that reduce the patient's psychomotor reactions and his ability to concentrate. In this connection, it is recommended to be careful and temporarily refuse to drive vehicles and complex mechanisms in the event of increased drowsiness, dizziness, vertigo, visual disturbances.

Application during pregnancy and lactation

The use of Lefoktsin is contraindicated during the period of gestation and breastfeeding.

Pediatric use

The use of Lefokcin in pediatric practice for the treatment of children and adolescents under the age of 18 is contraindicated.

With impaired renal function

Caution should be exercised when prescribing Lefoccin in patients with impaired renal function.

For the treatment of patients with impaired renal function with a creatinine clearance (CC) of 50 ml / min and below, a reduction in the dose of Lefoccin is required. Correction of the dosage regimen is carried out taking into account the CC and the dose recommended for the treatment of a specific disease in patients with CC more than 50 ml / min.

For violations of liver function

If liver function is impaired, dose adjustment is not required.

Use in the elderly

When prescribing Lefokcin in elderly patients, caution is required due to the presence of risk factors for prolongation of the QT interval in this category of patients.

Changing the dosage regimen for elderly patients is required only if the patient's CC is 50 ml / min and below.

Drug interactions

With simultaneous use with Lefokcin:

didanosine, medicines containing iron and zinc, magnesium, aluminum: taking medicines containing divalent or trivalent cations, including zinc or iron salts (drugs for the treatment of anemia), magnesium and / or aluminum (including antacids), or dosage forms of didanosine, which contain aluminum or magnesium as a buffer, it is recommended to produce it no later than 2 hours before or not earlier than 2 hours after the use of levofloxacin;
calcium salts: calcium salts practically do not affect the absorption of Lefokcin;
sucralfate: means for protecting the gastric mucosa can significantly weaken the effect of Lefokcin, therefore, sucralfate should be taken 2 hours after levofloxacin;
theophylline, fenbufen: drugs that lower the seizure threshold of the brain, including nonsteroidal anti-inflammatory drugs, can cause a pronounced decrease in the seizure threshold of the brain;
warfarin and other indirect anticoagulants (vitamin K antagonists): Taking indirect anticoagulants increases the risk of increased prothrombin time, international normalized ratio, and / or bleeding. To prevent undesirable effects, if it is necessary to use a combination of levofloxacin and indirect anticoagulants, it is necessary to carefully monitor blood coagulation parameters;
probenecid, cimetidine: under the influence of drugs that violate renal tubular secretion, the excretion of levofloxacin slows down (including when combined with probenecid - by 34%, cimetidine - by 24%). With normal renal function, this may not have clinical significance, caution should be observed if it is necessary to combine therapy with these agents in patients with renal failure;
cyclosporine: no dose adjustment of cyclosporine is required;
glucocorticosteroids: interaction with glucocorticosteroids significantly increases the risk of tendon rupture;
class IA and III antiarrhythmics, macrolides, tricyclic antidepressants, antipsychotics: drugs that prolong the QT interval should be used with caution;
digoxin, glibenclamide, ranitidine, warfarin: interaction with these agents does not cause clinically significant changes in the pharmacokinetics of levofloxacin;
glibenclamide and other oral hypoglycemic agents, insulin preparations: concomitant therapy with these agents increases the risk of hypoglycemia.

Analogs

The analogues of Lefoktsin are Tavanik, Glevo, Levolet, Haileflox, Floracid, Fleksid, Elefloks, Levostar, Remedia, Leflobact, Ashlev, Levoximed, Levofloxacin-Nova, Levofloxabol, Tanflomed, Leobag, etc.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C, protected from moisture.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Lefoktsin

Reviews about Lefokzin are predominantly positive. Patients indicate the effectiveness and rapid action of the drug in the treatment of diseases of infectious etiology. In some cases, there are reports of adverse events requiring the withdrawal of Lefokcin.

Price for Lefoccin in pharmacies

The price of Lefokcin for a package containing 5 tablets in a dose of 500 mg can range from 331 rubles.

Lefokcin: prices in online pharmacies

Drug name

Price

Pharmacy

Lefokcin 500 mg film-coated tablets 5 pcs.

208 RUB

Buy

Lefokcin 500 mg film-coated tablets 10 pcs.

216 r

Buy

Lefokcin tab. p.p. 500mg n5

282 r

Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!